Clinical Trial Detail

NCT ID NCT03666273
Title A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

Advanced Solid Tumor

cervical cancer

gastric adenocarcinoma

transitional cell carcinoma

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

Therapies

BAY1905254

BAY1905254 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.